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Purpose: Using data from the Continuing to Confront COPD International Physician and Patient 
Surveys, this paper describes physicians’ attitudes and beliefs regarding chronic obstructive 
pulmonary disease (COPD) prognosis, and compares physician and patient perceptions with 
respect to COPD.
Methods: In 12 countries worldwide, 4,343 patients with COPD were identified through 
systematic screening of population samples, and 1,307 physicians who regularly saw patients 
with COPD were sampled from in-country professional databases. Both patients and physicians 
completed surveys about their COPD knowledge, beliefs, and perceptions; physicians answered 
further questions about diagnostic methods and treatment choices for COPD.
Results: Most physicians (79%) responded that the long-term health outlook for patients 
with COPD has improved over the past decade, largely attributed to the introduction of better 
medications. However, patient access to medication remains an issue in many countries, and 
some physicians (39%) and patients (46%) agreed/strongly agreed with the statement “there 
are no truly effective treatments for COPD”. There was strong concordance between physicians 
and patients regarding COPD management practices, including the use of spirometry (86% of 
physicians and 76% of patients reporting they used/had undergone a spirometry test) and smok-
ing cessation counseling (76% of physicians reported they counseled their smoking patients at 
every clinic visit, and 71% of smoking patients stated that they had received counseling in the 
past year). However, the groups differed in their perception about the role of smoking in COPD, 
with 78% of physicians versus 38% of patients strongly agreeing with the statement “smoking 
is the cause of most cases of COPD”.
Conclusion: The Continuing to Confront COPD International Surveys demonstrate that while 
physicians and patients largely agreed about COPD management practices and the need for more 
effective treatments for COPD, a gap exists about the causal role of smoking in COPD.
Keywords: chronic obstructive pulmonary disease, physician survey, patient survey, beliefs, 
perceptions
Introduction
Although chronic obstructive pulmonary disease (COPD) is a preventable and treatable 
disease,1 it is associated with significant morbidity and mortality, giving rise to an 
enormous social and economic burden.1,2 In 2010, COPD was ranked as the third 
leading cause of mortality and the ninth leading cause of disability-adjusted life years 
lost worldwide.2,3
The evidence-based guidelines available to aid physicians in the management 
and treatment of patients are frequently not fully implemented in clinical practice, 
as demonstrated across many regions worldwide.4–11 Reasons for this include a lack 
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of familiarity with guidelines and a lack of confidence in 
implementation and access/time constraints,9–11 but have 
also been shown to be associated with physician percep-
tions and beliefs about COPD management. Yawn et al10 
reported that among 278 primary care physicians (PCPs) 
and practice nurses/assistants, only 15% thought COPD 
treatments were very or somewhat useful and 3% thought 
pulmonary rehabilitation was useful or very useful, despite 
its availability to 32% of those sampled. In a Swiss study 
of 455 PCPs, 52% stated that they were uncomfortable with 
smoking cessation counseling, 72% underused pulmonary 
rehabilitation programs, and the indications and effects of 
COPD treatments were poorly recognized.7
Few studies have investigated the perceptions and beliefs 
about COPD from both a physician and a patient perspec-
tive. Hernandez et al12 surveyed 58 respiratory specialists 
and 640 patients with COPD and reported that perceived 
knowledge needs and preferred methods of education differed 
between physicians and patients. For example, physicians 
identified smoking cessation counseling as an educational 
priority, while patients wanted to be informed more about 
their disease progression.
The Continuing to Confront COPD International Survey 
aimed to describe COPD disease burden and perceptions 
about the disease from both the patient and physician perspec-
tives across 12 countries. This paper describes physicians’ 
attitudes and beliefs regarding COPD prognosis and treat-
ment, and how physician and patient perceptions compare 
with respect to multiple aspects of COPD.
Methods
A detailed description of the study design, methodology, 
and response rates for the Continuing to Confront COPD 
International Physician and Patient Surveys have been 
reported previously.13,14 Briefly, both surveys were conducted 
during 2012–2013 in Brazil, France, Germany, Italy, Japan, 
Mexico, the Netherlands, Russia, South Korea, Spain, the 
UK, and the USA.
The Physician Survey sampled PCPs and respiratory spe-
cialists who regularly saw patients with COPD, emphysema, 
or chronic bronchitis (contact with 5 patients per month, on 
average) from in-country databases of professional associa-
tions to achieve an a priori 3:1 ratio of PCP to respiratory 
specialists in each country.13 In total, 1,307 physicians (74% 
PCPs, 26% respiratory specialists) agreed to participate. 
A single survey covering knowledge and behavior around 
diagnosis and treatment of COPD and beliefs about COPD 
risk and prognosis was translated into local language, 
and interviews were conducted online, by telephone, or 
face-to-face. The response rate by country ranged from 10% 
(USA) to 38% (Spain).
The Patient Survey was primarily designed to estimate 
the prevalence of COPD in each country, and therefore, 
patients with COPD were identified systematically by 
screening probability samples of households followed by 
telephone or face-to-face interviews of eligible patients. A 
single survey that incorporated questions about patients’ 
perception of their disease severity and its impact on daily 
living, and validated patient-reported outcome instruments 
to assess disease severity, medication adherence, and patient 
engagement was translated into local language.14 Eligible 
patients were adults aged 40 years and older who reported 
either 1) a physician diagnosis of COPD/emphysema or 
2) a physician diagnosis of chronic bronchitis, or 3) met a 
symptom-based definition of chronic bronchitis and either 
were taking respiratory medication for their condition or had 
chronic cough with phlegm most days. The Patient Survey 
identified 106,876 households with at least one person 
aged 40 years, of which 4,343 respondents fulfilled the 
earlier-mentioned case definition of COPD and completed 
the full survey. Response rates for the Patient Survey ranged 
from 25% (UK) to 74% (Brazil).
To elicit physician and patient perceptions regarding 
COPD, respondents were asked to indicate their level 
of agreement with a series of statements using a 4-point 
scale (strongly disagree, somewhat disagree, somewhat 
agree, strongly agree). The statements were not designed to 
have a “correct” answer, but rather to evaluate respondent 
perception. Most statements were based on the original 
Confronting COPD International Survey or other published 
surveys to allow for comparison across time points and dif-
ferent study populations.15–17
As the Patient Survey sample was identified from screen-
ing general population probability samples, we were able to 
weight the results included herein by age and sex according 
to the latest census data available in each country to obtain 
representative countrywide estimates. The Physician Survey 
results are not weighted as standardized reliable estimates 
of the universe of physicians in each country are not readily 
available for all countries.
The comparison between physician and patient perceptions 
on topics addressed in both surveys are qualitative in nature, 
as we did not have an a priori hypothesis about the expected 
concordance nor were we able to conduct statistical testing 
due to slight differences in the wording of questions between 
surveys.
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Results
Demographics
The demographic characteristics of the physician and patient 
samples have been described in detail elsewhere.13,14 Among 
the total physician sample, 75% were male, 81% practiced 
in an outpatient setting, and 54% worked in a multispecialty 
practice, with the majority of practices found in small cities/
towns (50%) or in central cities (42%). Approximately half 
had graduated from medical school later than 1990.
Patient respondents had a mean age of 61 years; 48% 
were male, with a mean body mass index of 26.9 (standard 
deviation, 6.5) kg/m2. Smoking status was reported as 36% 
nonsmokers, 37% former smokers, and 28% current smokers. 
Most commonly reported comorbidities were hypertension 
(45%) and asthma (42%).
Physician beliefs about COPD prognosis 
and treatment
The majority of physicians surveyed (79%) reported that they 
believe the long-term health outlook for patients with COPD 
has improved compared to 10 years ago, and this view was 
generally consistent across countries (range, 55%–94%; Table 
S1). The most common reasons given for the improved outlook 
were “better medications for COPD” (86%; range, 75%–90%) 
and “increased smoking cessation/less passive smoking” (28%; 
range, 15%–51%). Other common reasons included “more 
public acceptance and knowledge about COPD” (22%) and 
“better diagnostics/earlier diagnosis of COPD” (21%). Despite 
the view of an improved health outlook for patients with COPD, 
a large proportion of physicians still felt that their patients find 
it difficult to cope with their disease (Table 1 and Table S2).
While physicians largely attributed the improved progno-
sis to the availability of better medications, unmet needs for 
modifying the natural history of the disease were noted; about 
half (46%; range, 28%–81%) agreed or somewhat agreed that 
“there are no current treatments that can reduce mortality 
or halt COPD progression” (Table 1 and Table S2). With 
regard to COPD physiology, physicians universally agreed 
that “inflammation is a key component of COPD that should 
be treated” (92%; range, 86%–97%) and that “more frequent 
exacerbations are linked to a greater loss in lung function” 
(93%; range, 86%–100%) (Table 1 and Table S2).
When queried about patient access to medication, one in 
three physicians (30%) stated that none of their patients had any 
issues accessing the treatments they prescribed; 7% reported that 
more than half their patients could not access preferred treatments 
(Figure 1). However, these proportions varied greatly by country, 
with the highest rates of treatment access restrictions reported in 
the USA, Mexico, and Brazil (Table S3). The most frequently 
reported barrier to medication access across most countries was 
related to cost (“too expensive for patient” or “insurance barri-
ers”). Exceptions included Italy, where “patient refusal to use 
prescribed medicine”, and the Netherlands where “side effects 
of preferred treatment” was commonly cited. As well, one-third 
to one half of physicians in the UK, Mexico,  Russia, and South 
Korea mentioned that they were not able to use preferred treat-
ments as they were “not recommended by local guidelines” or 
were “not on the clinic/hospital formulary”.
When asked to estimate the percentage of their patients 
on COPD maintenance medication who fully comply with 
treatment instructions, only 15% reported that more than 
three-quarters were fully compliant (range, 5%–26%) 
(Table S4). Major problems associated with poor compliance 
were reported to be “poor inhaler technique” (60%; range, 
34%–87%), “low patient education/poor understanding of the 
disease” (57%; range, 47%–69%), “difficulties in managing 
multiple dosing regimens” (52%; range, 40%–64%), “no 
perceived benefit of treatment” (46%; range, 30%–66%), and 
“medication costs” (44%; range, 6%–89%). While physicians 
in most countries regarded “troublesome side effects” as a 
minor problem affecting patient compliance with treatment 
instructions, over 50% of physicians in Russia and Japan 
reported it as a major problem. “Medication costs” was 
reported as a leading challenge related to compliance by fewer 
than 10% of physicians in France, UK, and the Netherlands, in 
contrast to more than 80% in the USA, Mexico, and Brazil.
Table 1 Physician beliefs and knowledge about COPD prognosis and treatment: Continuing to Confront COPD International survey, 
2012–2013
Question Response (%)
Strongly  
agree
Somewhat  
agree
Somewhat  
disagree
Strongly 
disagree
no current treatments reduce mortality or halt COPD progression 16 30 34 18
Inflammation is a key component of COPD and should be treated 58 34 5 1
More frequent exacerbations are linked to a greater loss in lung function 55 38 6 1
It is difficult for most patients to cope with COPD 29 50 19 2
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Comparison between physician 
and patient beliefs and reporting 
of management practices
Several questions about COPD perceptions were asked in 
both the physician and patient surveys. A similar propor-
tion of both physicians (39%) and patients (46%) strongly 
or somewhat agreed with the statement “there are no truly 
effective treatments for COPD” (Figure 2). There was 
some variation across countries in physician response 
from 19% (USA) to 72% (Russia), while this belief among 
patients ranged from 26% (Italy) to 63% (South Korea) 
(Table S5).
In contrast, there was a considerable difference between 
physicians and patients regarding their views on the statement 
“smoking is the cause of most cases of COPD” with 78% of 
physicians strongly agreeing, compared with only 38% of 
patients (Figure 3). One-third of patients somewhat (17%) or 
strongly (14%) disagreed with this statement, compared with 
100%
80%
60%
40%
20%
0%
30%
44%
19%
5%
2% 1% 2% 4% 5% 5%
17%
82%
39%
55%
5%
1%
5%
1%
1%
1%
15%
67%
12%
1%
2%
35%
62%
16%
62%
16%
32%
36%
27%
18%
48%
29%
6% 6%
5% 1%3%
26%
4%
47%
12%
32%
48%
5%
13%
34%
47%
9%
37%
49%
5% 5%
Total
N=1,307
USA
N=200
Mexico
N=101
Brazil
N=101
France
N=100
Germany
N=100
Italy
N=100
Spain
N=100
Q. What percent of your COPD patients cannot access the treatment you wish to prescribe them?
UK
N=100
NL
N=101
Russia
N=100
Japan
N=101
SK
N=103
39%
76%–100%
51%–75%
26%–50%
1%–25%
None
65%
Figure 1 Physician perception about patient access to treatment: Continuing to Confront COPD International survey, 2012–2013.
Note: Columns do not always sum to 100% due to rounding or missing values.
Abbreviations: nl, the netherlands; sK, south Korea.
100 Strongly agree
9%
30% 33% 28%
17%
29% 27%
22%
Somewhat agree Somewhat disagree Strongly disagree
80
60
Pe
rc
en
t
40
20
0
Physicians
N=1,307
Physician and patient question: please indicate whether you strongly agree, somewhat
agree, somewhat disagree, or strongly disagree with the following statement: “there are no
truly effective treatments for COPD”.
Patients
N=4,343
Figure 2 Comparison of physician and patient beliefs about treatment effectiveness: Continuing to Confront COPD International survey, 2012–2013.
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3% of physicians (Table S5). Given this large disparity, we 
explored patient characteristics associated with disagreement 
in a multivariate logistic regression model (Table S6). Fac-
tors independently associated with disagreeing that “smok-
ing is the cause of most cases of COPD” were as follows: 
never smoking (OR [odds ratio], 4.4; 95% CI [confidence 
interval], 3.6–5.4), former smoking (OR, 1.6; 95% CI, 
1.3–1.9), exposure to dust and fumes at home or in the work-
place (OR, 1.2; 95% CI, 1.0–1.4), and female sex (OR, 1.5; 
95% CI, 1.3–1.7). Younger patients and those with more 
than secondary school education were also more likely to 
disagree that smoking is the primary cause of COPD. In 
contrast, patients with a physician diagnosis of COPD (OR, 
0.6; 95% CI, 0.4–0.7) or chronic bronchitis (OR, 0.5; 95% CI, 
0.4–0.6) were less likely than those who qualified based on a 
symptom-based definition of chronic bronchitis to disagree 
about the causal role of smoking in COPD.
Questions regarding how physicians manage COPD, 
including smoking cessation counseling for smoking 
patients, and the use of lung function tests, were also asked 
of both physicians and patients. Physicians and patients 
largely agreed about the provision of smoking cessation 
counseling to current (or recently quitting) smokers (Figure 4 
and Table S5). Sixty-seven percent (range, 44%–88%) of 
physicians reported that they counseled their smoking 
patients at every clinic visit and 29% (range, 11%–48%) 
Strongly agree
Physicians
N=1,307
Pe
rc
en
t
100
80
60
19%
78%
38%
28%
2%
17% 14%
1%
40
20
0
Patients
N=4,343
Somewhat agree Somewhat disagree Strongly disagree
Physician and patient question: please indicate whether you strongly agree, somewhat
agree, somewhat disagree, or strongly disagree with the following statement: “smoking is
the cause of most cases of COPD”.
Figure 3 Comparison of physician and patient beliefs about smoking as a risk factor for COPD: Continuing to Confront COPD International survey, 2012–2013.
100
80
Every visit Yes
No/UnknownMost visits
Some visits/Once a year/
When symptoms worsen
60
67%
71%
29% 29%
3%
Pe
rc
en
t
40
20
0
Physicians
N=1,307
Physician question: How often do you 
bring up smoking cessation with your 
patients who smoke?
Patient question: Has your doctor discussed stopping
smoking with you in the past 12 months? (among
current smokers or former smokers who quit in the
past year)
Patients
N=1,272
Figure 4 Comparison of physician- and patient-reported smoking cessation counseling practices: Continuing to Confront COPD International survey, 2012–2013.
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at most visits. This was corroborated by 71% (range, 
35%–87%) of smoking patients, indicating that they had 
received smoking cessation counseling in the past year. 
When examining patient–physician comparisons within indi-
vidual countries, Japanese, Dutch, and German physicians 
were slightly less likely to report that they counseled their 
patients at every/most clinic visit, which corresponded with 
rates of smoking cessation counseling reported by patients 
in these same countries.
When questioned about lung function testing practices, 
the majority of physicians (86%) and patients (76%) reported 
that they used (or had undergone) spirometry testing (Figure 5 
and Table S5). Physician responses were consistent across 
countries (85% reported spirometry use) except Italy 
(37%) and France (63%), where a high proportion of PCPs 
indicated that this testing option was not available in their 
practice. These findings from France and Italy were supported 
by responses from the patient survey, as French (28%) and 
Italian (56%) patients were among the lowest to report that 
they had received lung function testing. Of interest, discor-
dance between physicians and patients on this topic was 
seen in Russia (100% of physicians reported that they use 
spirometry versus 59% of patients indicating they received 
a lung function test) and Mexico (88% of physicians versus 
57% of patients).
Discussion
The Continuing to Confront COPD International Surveys pro-
vide an insight into physicians’ views about COPD outlook 
and management, and an opportunity to compare physician 
and patient attitudes and beliefs about COPD. Key findings 
from the physician survey include a perceived improvement 
about the health outlook for patients with COPD, primarily 
associated with the availability of better treatments. Despite 
these better treatments, physicians highlighted patient access 
to preferred treatment and patient compliance to maintenance 
treatment as problematic in many regions. Across most 
countries, physicians reported regular use of spirometry 
to diagnose COPD and indicated that smoking cessation 
counseling to smoking patients was a routine part of their 
COPD management; these findings were corroborated by the 
patient survey. We observed discordance between physicians 
and patients regarding the statement “smoking is the cause 
of most cases of COPD”.
The majority of physicians reported that the long-term 
health outlook for patients with COPD has improved com-
pared with 10 years ago, and while this was largely attributed 
to the availability of better medications (86% of physicians), 
approximately a quarter also attributed the better outlook to 
smoking cessation and improved public awareness about 
COPD. Only a third of physicians felt that their patients had 
no problems accessing preferred treatments; cost and issues 
of insurance coverage were reported as the biggest factors 
associated with problems of access to medicines. These data 
varied greatly by country; physicians from USA, Brazil, and 
Mexico reported the most issues with access (90% physi-
cians) compared with lower reporting in the UK (34%), Italy 
(12%), and the Netherlands (11%), reflecting differences in 
health care delivery and direct costs to patients between coun-
tries (eg, national versus privatized systems). In the COPD 
100
80
86%
76%
14%
24%
60
Pe
rc
en
t
40
20
0
Physicians
N=1,307
Physician question: Do you use spirometry 
in diagnosing COPD normally?
Patient question: Have you ever had your
lungs tested – where you blow hard into
a tube, called a lung function test?
Patients
N=4,343
Yes
No/not available
Yes
No
Figure 5 Comparison of physician- and patient-reported lung function testing practices: Continuing to Confront COPD International survey, 2012–2013.
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Resource Network Needs Assessment Survey conducted in 
the USA in 2003–2004, approximately two-thirds believed 
that reimbursement standards for medical management of 
patients with COPD were inadequate or very unreasonable, 
showing that this issue is pervasive in the USA and continues 
to be a barrier to COPD care.16
Only 15% of physicians in our survey reported that more 
than three-quarters of their patients on maintenance therapy 
for COPD were fully compliant in taking their medications, 
highlighting noncompliance as a major challenge in COPD 
management. Across countries, the two most common 
reasons associated with noncompliance were poor inhaler 
technique and poor patient education/understanding of 
disease. These findings are consistent with those reported 
in a recent review of treatment adherence issues in COPD, 
in which on average 40%–60% of patients were considered 
adherent to their medications and only one in ten of those 
prescribed a metered dose inhaler was reported to use it com-
pletely correctly.18 Similar to our findings, previous reviews 
cite many possible reasons for poor compliance, including 
those related to medicine/device factors (eg, difficulties with 
inhalers, complex regimens, side effects) and patient factors 
(eg, misunderstanding medication instructions, undiscussed 
fears/concerns, cultural issues).18,19 To achieve optimal 
compliance, patients should have a clear understanding of 
the need for their treatment, which takes account of specific 
concerns, and treatment should be convenient and as easy 
to use as possible.20
For topics covered in both surveys, there was good agree-
ment between responses about COPD treatment effective-
ness, smoking cessation practices, and use of spirometry, both 
overall and within countries, suggesting a good degree of 
credibility in the self-reported physician responses. Approxi-
mately two fifths of both patients and physicians strongly 
or somewhat agreed with the statement “there are no truly 
effective treatments for COPD”, despite many physicians 
noting that the introduction of better treatments has played 
a role in improving the long-term health outlook for patients 
with COPD. A similar pattern was reported by Barr et al16 
in the COPD Resource Network Needs Assessment Survey, 
where 68% of physicians reported an improved COPD out-
look due primarily to better medications, yet almost a third 
agreed or strongly agreed that “there are no truly effective 
treatments for COPD”.
Regarding physician diagnosis and management prac-
tices, the high level (86%) of self-reported use of spirometry 
by physicians in the Continuing to Confront COPD Inter-
national Physician Survey13 was corroborated with 76% of 
patients reporting that they had undergone a lung function 
test. The provision of smoking cessation counseling to 
smokers was also reported by the majority of both physicians 
and patients; however, a key discordance was observed in 
their beliefs about the statement “smoking is the cause of 
most cases of COPD”. Other published studies comprised 
primarily of patients with COPD who currently smoke have 
also shown that patients more often cite non-smoking-related 
causes of COPD than physicians.16,21 There was some geo-
graphic variability regarding patient belief about the role of 
smoking, but this did not appear to be related to smoking 
prevalence rates in a particular country. For example, Japan 
and Korea have some of the highest global smoking rates,22 
and respondents in these countries were also most likely to 
disagree with the statement (Table S5); however, this pattern 
did not hold in Russia, the UK, Spain, and France, which 
also feature medium-to-high smoking prevalence yet were 
least likely to disagree about the role of smoking in COPD. 
Also, the results did not track geographically with countries 
that have a higher use of biofuels, another recognized risk 
factor associated with COPD.23 Thus, it appears that other 
patient factors may play a role in patient beliefs. We explored 
this further in our sample and identified that self-reported 
nonsmokers were the most likely group to disagree with the 
statement “smoking is the cause of most cases of COPD”, 
even after adjusting for other patient factors, and this finding 
was consistent in all countries (ORs for nonsmokers versus 
smokers ranged from 1.5 to 11.7; full data not shown). 
Despite implementation of awareness campaigns about 
the risks of smoking,24 it may not be surprising that some 
nonsmokers express doubt that smoking is a primary cause 
of COPD given their lack of personal smoking exposure. 
Similarly, we saw that ex-smokers who may have quit years 
before their diagnosis were also slightly more likely to dis-
agree with this statement. We also observed that patients 
with a physician-confirmed diagnosis of COPD or chronic 
bronchitis were half as likely as those who qualified with 
symptoms only to deny a causal role of smoking in COPD, 
suggesting that educational messages about the importance 
of smoking cessation are more effectively reaching patients 
with COPD than the general public. These results can be 
helpful in identifying groups, such as nonsmokers, women, 
and younger adults, who may most benefit from targeted 
educational interventions about the risks of smoking.
Our findings must be interpreted within the limitations of 
this type of survey. As discussed in detail in previous publica-
tions about this survey, the representativeness of the samples 
within certain countries may be limited due to variable 
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response rates in the Patient and Physician surveys.13,14 In 
addition, the comparison of physicians’ and patients’ per-
ceptions may be impacted by differences in knowledge and 
priorities between these groups. For example, patients and 
physicians will bring underlying assumptions about treatment 
effectiveness that may impact their responses to statements 
such as “there are no truly effective treatments for COPD”. 
Similarly, beliefs about smoking as a cause of the majority 
of cases of COPD will be subject to a patient’s personal risk 
factor profile, as well as regional variation in the frequency 
of other established risk factors such as biomass fuel and 
other occupational exposures.
In conclusion, the Continuing to Confront COPD 
International Surveys demonstrated that physician percep-
tion about the health outlook for patients with COPD has 
improved in the past decade, largely attributed to improved 
medications, although patient access to therapy remains 
problematic in many areas. Many physicians and patients 
agreed with the statement that “there are no truly effective 
COPD treatments”, suggesting that further efforts to move 
toward a precision medicine approach for treating specific 
COPD phenotypes are warranted. There was a considerable 
gap between physicians’ and patients’ perceptions about 
whether smoking is the cause of the majority of cases of 
COPD, highlighting a need for enhanced and targeted patient 
education about the risks of smoking.
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Table S6 Multivariate model of predictors of patient’s 
disagreement* with the statement “smoking is the cause of most 
cases of COPD”: Continuing to Confront COPD International 
survey, 2012–2013
Patient characteristic Odds ratio (95% CI)
Smoking status
Current smoker ref
Former smoker 1.6 (1.3, 1.9)
never smoker 4.4 (3.6, 5.4)
Exposed to dust or fumes from cooking, burning, mining, 
welding, etc, for a year or more
Yes 1.2 (1.0, 1.4)
no ref
Age (years)
40–49 1.8 (1.4, 2.2)
50–59 1.6 (1.3, 1.9)
60–69 1.1 (0.9, 1.4)
70+ ref
Sex
Male ref
Female 1.5 (1.3, 1.7)
Education level
high school (secondary school) or less ref
some/completed university or technical training 1.3 (1.1, 1.5)
Qualifying diagnosis
Physician-diagnosed COPD 0.6 (0.4, 0.7)
Physician-diagnosed chronic bronchitis 0.5 (0.4, 0.6)
Symptom-based definition of chronic bronchitis ref
Notes: all factors associated with disagreement in univariate analysis were entered 
into a backward elimination model; only statistically significant variables (displayed 
above) and country were retained in the final model; *strongly disagreed or 
somewhat disagreed with the statement.
Abbreviations: COPD, chronic obstructive pulmonary disease; CI, confidence 
interval; ref, reference category.
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